These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37832344)

  • 1. Characterization and immunogenicity of a novel chimeric hepatitis B core-virus like particles (cVLPs) carrying rotavirus VP8*protein in mice model.
    Latifi T; Jalilvand S; Golsaz-Shirazi F; Arashkia A; Kachooei A; Afchangi A; Zafarian S; Roohvand F; Shoja Z
    Virology; 2023 Nov; 588():109903. PubMed ID: 37832344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma VP8∗-Binding Antibodies in Rotavirus Infection and Oral Vaccination in Young Bangladeshi Children.
    Lee B; Colgate ER; Carmolli M; Dickson DM; Gullickson S; Diehl SA; Ara R; Alam M; Kibria G; Abdul Kader M; Afreen S; Ferdous T; Haque R; Kirkpatrick BD
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):127-133. PubMed ID: 34904667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and characterization of a novel truncated rotavirus VP4 for the development of a recombinant rotavirus vaccine.
    Li Y; Xue M; Yu L; Luo G; Yang H; Jia L; Zeng Y; Li T; Ge S; Xia N
    Vaccine; 2018 Apr; 36(16):2086-2092. PubMed ID: 29555220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and protective efficacy in an animal model of a novel truncated rotavirus VP8 subunit parenteral vaccine candidate.
    Xue M; Yu L; Che Y; Lin H; Zeng Y; Fang M; Li T; Ge S; Xia N
    Vaccine; 2015 May; 33(22):2606-13. PubMed ID: 25882173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
    Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
    Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of P[8], P[4], and P[6] VP8* genes of human rotaviruses globally reported during 1974 and 2017: possible implications for rotavirus vaccines in development.
    Velasquez DE; Jiang B
    Hum Vaccin Immunother; 2019; 15(12):3003-3008. PubMed ID: 31124743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.
    Parez N; Fourgeux C; Mohamed A; Dubuquoy C; Pillot M; Dehee A; Charpilienne A; Poncet D; Schwartz-Cornil I; Garbarg-Chenon A
    J Virol; 2006 Feb; 80(4):1752-61. PubMed ID: 16439532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-administration of rotavirus nanospheres VP6 and NSP4 proteins enhanced the anti-NSP4 humoral responses in immunized mice.
    Afchangi A; Jalilvand S; Arashkia A; Latifi T; Farahmand M; Abolghasem Shirazi MM; Mousavi Nasab SD; Marashi SM; Roohvand F; Shoja Z
    Microb Pathog; 2022 Feb; 163():105405. PubMed ID: 35045328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
    Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
    Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reverse Genetics Approach for Developing Rotavirus Vaccine Candidates Carrying VP4 and VP7 Genes Cloned from Clinical Isolates of Human Rotavirus.
    Kanai Y; Onishi M; Kawagishi T; Pannacha P; Nurdin JA; Nouda R; Yamasaki M; Lusiany T; Khamrin P; Okitsu S; Hayakawa S; Ebina H; Ushijima H; Kobayashi T
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33087468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model.
    Xue M; Yu L; Jia L; Li Y; Zeng Y; Li T; Ge S; Xia N
    Hum Vaccin Immunother; 2016 Nov; 12(11):2959-2968. PubMed ID: 27435429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant Subunit Rotavirus Trivalent Vaccine Candidate: Physicochemical Comparisons and Stability Evaluations of Three Protein Antigens.
    Agarwal S; Hickey JM; Sahni N; Toth RT; Robertson GA; Sitrin R; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):380-393. PubMed ID: 31400347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice.
    Xia M; Huang P; Jiang X; Tan M
    Vaccine; 2019 Jul; 37(30):4103-4110. PubMed ID: 31201052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates.
    Wen X; Cao D; Jones RW; Li J; Szu S; Hoshino Y
    Vaccine; 2012 Sep; 30(43):6121-6. PubMed ID: 22885016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Nanoparticle-Based Trivalent Vaccine Targeting the Glycan Binding VP8* Domains of Rotaviruses.
    Xia M; Huang P; Jiang X; Tan M
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33419150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.
    Lappalainen S; Tamminen K; Vesikari T; Blazevic V
    Hum Vaccin Immunother; 2013 Sep; 9(9):1991-2001. PubMed ID: 23777748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral immunization of mice with Lactococcus lactis expressing the rotavirus VP8* protein.
    Rodríguez-Díaz J; Montava R; Viana R; Buesa J; Pérez-Martínez G; Monedero V
    Biotechnol Lett; 2011 Jun; 33(6):1169-75. PubMed ID: 21302132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice.
    Bertolotti-Ciarlet A; Ciarlet M; Crawford SE; Conner ME; Estes MK
    Vaccine; 2003 Sep; 21(25-26):3885-900. PubMed ID: 12922123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults.
    Fix AD; Harro C; McNeal M; Dally L; Flores J; Robertson G; Boslego JW; Cryz S
    Vaccine; 2015 Jul; 33(31):3766-72. PubMed ID: 26065919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.